In neurons, the selective translocation of Tau mRNA toward axons is due to the presence of a nucleotide sequence located in its 3' untranslated region and serving as axonal targeting element. Using this RNA sequence as a probe by a Northwestern approach, we have detected several proteins that interact with the targeting RNA element and could potentially be involved in Tau mRNA translocation, translation halting, and/or stabilization. Among them, two proteins were identified as the interleukin enhancer binding factor 3 (Ilf3) and NF90, two isoforms derived from a single gene product through alternative splicing. Each protein comprises two doublestranded RNA binding motifs that can interact with the predicted stem-loop secondary structure of the axonal targeting element. Specific antibodies raised against common or specific peptide sequences showed that both Ilf3 and NF90 are polymorphic proteins that are detected in neuronal nuclei and cell bodies, as well as in the proximal neuritic segments. This observation favors the idea that Ilf3 and NF90 are part of a protein complex that escorts Tau mRNA toward the axon.
A large number of amino acid sequences have been shown to act as signals that target proteins to specific cellular compartments. Besides this signal-directed trafficking of proteins, mRNAs are also actively transported in cells, leading them to specific subcellular destinations. In this case, following their delivery at specific places and the subsequent release of their translational inhibition, specific proteins can be produced and accumulated in particular cell areas. Numerous examples of transport and accurate subcellular localization of mRNAs have been documented (for review, see refs 3 and 4). In the case of Tau proteins, it has been shown that their axonal localization is due to the prior transport of their mRNAs to the proximal segment of the neuronal compartment, by contrast to tubulin mRNA, which is restricted to the cell body or MAP2 mRNA, which extends into dendrites (5) . The selective targeting of Tau mRNA toward the axon is due to the presence of a 91-nucleotide sequence located within its 3' untranslated region (6) . The introduction into neuronal cells of this sequence fused to a reporter mRNA leads to the restricted accumulation of the reporter message into the proximal segment of axons, indicating that this RNA sequence behaves as a potent axonal targeting element (ATE). A somewhat larger sequence of 240 nucleotides, encompassing the 91-nucleotide ATE sequence, is responsible for Tau mRNA stabilization (7) . Within this region, the AU-rich sequence was shown to bind the RNA-stabilizing HuD protein, the neuronal homologue of Elav-like protein (8) . In addition, it has also been demonstrated that MT integrity is required for Tau mRNA targeting (9) , that MTs bind the embryonic lethal abnormal vision-like (ELAV-like) HuD-Tau mRNA complex (8) , and that the translocation of Tau RNP granules requires the presence of KIF3A, a kinesin-related motor protein involved in anterograde transport (10) , suggesting that Tau mRNA is conveyed along these cytoskeletal tracks to reach its destination.
To analyze the molecular mechanisms underlying Tau mRNA targeting, we have searched for trans-acting proteins that bind specifically to ATE and could thus mediate the routing and accompany Tau mRNA during its transport as an RNA granule (11) . Using UV cross-linking approaches, several ATE binding proteins (ATE-BP), such as the HuD protein (8) , have previously been identified. In this paper, we have followed a complementary Northwestern blotting approach in which radioactively labeled ATE was used as an RNA probe to be overlaid onto mouse brain proteins separated by 1-D and 2-D PAGE. Among the few ATE-BPs specifically bound by the radioactive RNA probe, three proteins-p110, p95, and p80-exhibited a particularly strong binding affinity. In a first step, p110 was extensively purified and identified as the 911 aa-long interleukin enhancer binding factor 3 (Ilf3, also referred as NFAR2/NF110) (12) . Its detection by the ATE probe may be explained by the presence of two double-stranded RNA binding motifs (dsRBM). Indeed, secondary structure prediction analysis of ATE suggested that this RNA sequence could fold into a stem-loop motif. On the other hand, antibodies raised against Ilf3 amino-terminal and central peptides that cross-reacted with p95 led us to assign this protein to NF90/NFAR1, a splice variant polypeptide of 716 residues derived from the same Ilf3 gene (13) . This assumption was confirmed by partial immunodepletion of p95 from a soluble neuronal fraction following by Northwestern blot assay. Another antibody raised against the specific Ilf3 carboxy-terminal peptide decorated cell bodies and axonal proximal segments in cultured primary neuronal cells, thus strengthening the idea that Ilf3 is indeed a component of the protein complex that escorts Tau mRNA toward the axon. The third major protein detected in our Northwestern assay, p80, is not yet identified, but its lack of crossreactivity with the above-cited antibodies suggests it represents a protein species unrelated to Ilf3 and NF90.
MATERIALS AND METHODS

Purification of microtubule proteins
Tubulin and total MAPs were prepared from a 150,000g supernatant of adult mouse brain by MT assembly (14) in MEM buffer (50 mM MES, pH 6.7, 2 mM EGTA, 1 mM MgCl 2 ) containing 1 mM GTP, 25% (v/v) glycerol and a cocktail of protease inhibitors [10 µg.ml -1 aprotinin, 10 µg.ml -1 leupeptin, 1 mM 4-(2-aminoethyl) benzene sulfonyl fluoride]. After centrifugation, MT were resuspended in PEM buffer (75 mM PIPES, pH 6.7, 2 mM EGTA, 1 mM MgCl 2 ) containing 1 mM GTP and 20 µM Taxol to stabilize them. MAPs were released from MTs by two successive incubations at 37°C for 30 min in the presence of 0.1 M NaCl and then 0.5 M NaCl (Fig. 1) .
Protein concentrations were determined using the bicinchoninic acid method (Micro BCA Protein Assay Reagent Kit, Pierce, Rockford, IL), bovine serum albumin being used as standard.
1-D and 2-D PAGE
Protein separation by 1-D (15) or 2-D (16) PAGE was carried out as described previously (17) . In these experiments, nonequilibrium pH gradient electrophoresis (NEPHGE) gels were prepared with 1.6% and 0.4% (w/v) of 3.5-10 and 5-8 carrier ampholytes, respectively. Electrotransfer of proteins onto nitrocellulose membranes (Hybond C, Amersham Biosciences, Little Chalfont, UK) was performed essentially as described (18) . Blots were saturated in TBS-T (20 mM Tris, pH 7.5, 136.8 mM NaCl, 0.1% v/v Tween 20) containing 2% (w/v) low-fat milk. Antibodies were incubated in TBS-T overnight at room temperature and revealed with secondary antibodies (Biosys, Compiègne, France) by the chemiluminescence method. Silver staining was performed as previously described (19) .
In vitro transcription of the ATE probe
pBS
+ DNA (1 µg) containing the complete ATE sequence corresponding to the I fragment of rat Tau mRNA (6) linearized by Sty I digestion was transcribed in vitro in the presence of [ 32 P]-uridine triphosphate (NEN) using an RNA transcription kit (Stratagene, La Jolla, CA), according to the manufacturer's instructions.
Northwestern blot assay
After 1-D or 2-D PAGE and electrotransfer as described above, nitrocellulose membranes were blocked overnight at room temperature in Northwestern buffer (10 mM Tris-HCL, pH 7.5, 150 mM KCl, 5 mM MgCl 2 , 0.1% w/v gelatin, 0.1% v/v Tween 20) containing salmon sperm DNA (50 µg.ml -1 ). Membranes were incubated for 2 h at room temperature in the Northwestern buffer supplemented with yeast tRNA (50 µg.ml -1 ) and containing the [ ), then washed in Northwestern buffer two times for 5 min each at room temperature and for 2 h at 45°C. Radioactive ATE probe bound to proteins was revealed by autoradiography. Quantification of ATE probe binding was done by cutting the membrane and determining the bound radioactivity.
Purification of mouse Ilf3
Figure 3 outlines the purification of mouse Ilf3. With the exception of step 5 below, all steps were carried out at 4°C. All samples were cleared 30 min at 40,000g before loading on chromatography columns. A protease inhibitor cocktail (10 µg.ml -1 aprotinin, 10 µg.ml -1 leupeptin, 1 mM 4-(2-aminoethyl) benzene sulfonyl fluoride) was added to all buffers and samples, with the exception of the chromatography buffers.
In step 1, brains from 15-day-old mice were collected rapidly and homogenized in a glass-Teflon Potter with 2 ml.g -1 of tissue of BEM buffer (50 mM BICINE, pH 9.0, 2 mM EGTA, 1 mM MgCl 2 ) supplemented with 0.5 M NaCl and 0.5‰ (v/v) Triton X-100. After 12 strokes at 1200 rpm, the extract was centrifuged at 3000g for 30 min, and the S1 supernatant was again centrifuged at 150,000g for 30 min.
In step 2, the 150,000g supernatant (referred to as S2-BEM) diluted 1:1 with BEM buffer was treated by increasing the sodium citrate concentration progressively up to 1 g.ml -1 . The precipitate was recovered by centrifugation at 15,000g for 15 min. The C3 pellet was resuspended in MEM buffer (50 mM MES, pH 6.7, 2 mM EGTA, 1 mM MgCl 2 ) supplemented with 50 mM NaCl and 0.5‰ (v/v) Triton X-100.
In step 3, the resuspended C3 pellet was loaded, at a flow rate of 5 ml.min -1 , onto an anionexchange column (SP column, Amersham Biosciences) equilibrated in MEM buffer containing 50 mM NaCl and 0.5‰ (v/v) Triton X-100. The column was then washed with 5 column volumes of the same buffer at the same flow rate. A linear gradient was developed from 50 to 500 mM NaCl in 9 column volumes, followed by a 1 M NaCl final step. The positive fractions determined by Northwestern blotting assay were pooled to yield the SP fraction.
In step 4, after dilution with MEM buffer containing 0.2‰ (v/v) Triton X-100 to lower the NaCl concentration to 50 mM and Triton X-100 to 0.3‰ (v/v), the SP fraction was loaded onto a cation-exchange column (MonoQ column, Amersham Biosciences) at a flow rate of 0.4 ml.min -1 . The column was then washed with 3 column volumes of the same buffer at the same flow rate, and a linear gradient was developed from 50 to 500 mM NaCl in 9 column volumes, followed by a 1 M NaCl final step. The positive fractions determined by Northwestern blotting assay were pooled to give the MonoQ fraction.
In step 5, the Mono-Q fraction was adjusted to 0.6 M ammonium sulfate and submitted to hydrophobic interaction chromatography. The sample was loaded onto a phenyl sepharose column (Amersham Biosciences) at a flow rate of 1 ml.min -1 , and the column was washed with 10 column volumes of MEM buffer containing 0.2 M NaCl and 0.6 M ammonium sulfate. A linear gradient was developed from 0.6 to 0 M ammonium sulfate in 15 column volumes, followed by a 0 M ammonium sulfate final step. The positive fractions determined by Northwestern blotting assay were pooled to yield the HIC fraction.
In step 6, proteins from the HIC fraction were submitted to reverse-phase HPLC on a C4-BU300 column (Brownlee Columns, Perkin Elmer, Boston, MA, 100×4.6 mm) with a C4-BU300 precolumn (Brownlee Columns, 30×4.6 mm) at a flow rate of 1 ml.min -1 . HIC fraction was injected in 95% buffer A (0.1% trifluoroacetic acid in water) and 5% buffer B (0.1% trifluoroacetic acid and 70% acetonitrile in water) and was then eluted with a linear gradient of 95% buffer A/5% buffer B to 0% buffer A/100% buffer B in 30 min. The positive fractions determined by Northwestern blotting assay were pooled to give the RP fraction.
Protein sequencing
Proteins from the S2-BEM supernatant (Fig. 3) or the RP fraction (see above) were separated by 2-D or 1-D PAGE, and then the region of interest was cut out of the gel and submitted to a digestion with the endolysin C protease for 18 h at 35°C in the appropriate buffer (50 mM Tris HCl, pH 8.6, 0.03% w/v SDS). After electroelution from the polyacrylamide gel, the resulting peptides were submitted to an anion exchange coupled to a reverse-phase HPLC on a DEAE column and a C18 column. Peptides were injected in 0.1% trifluoroacetic acid and 2% acetonitrile and then eluted with a linear gradient from 2% to 45% acetonitrile/0.1% trifluoroacetic acid in 15 min. The sequences of some peptides were determined by 10-15 cycles of Edman degradation (J. d'Alayer, Service de microséquençage, Institut Pasteur, Paris, France), and the corresponding protein was identified by comparison with database sequences.
Preparation of polyclonal antibodies
Two different polyclonal antibodies were generated using synthetic Ilf3 peptides as immunogens after their conjugation with thyroglobuline. Rabbits were immunized according to the Eurogentec (Liège, Belgium) procedure. Antibody Ab78 was raised against a mix of two peptides corresponding to the amino-terminal aa 60-70 (DWIDEQEKGNS) and central aa 522-536 (FPSDATTEQGPILTK) residues of Ilf3 sequence (12). Antibody Ab83 was raised against the carboxy-terminal aa 898-911 Ilf3 sequence (YSRNTEHSMNYQYR).
P19 cells culture
Mouse teratocarcinoma P19 cells were grown in DME medium containing 10% (v/v) heatinactivated fetal calf serum, 100 U.ml -1 penicillin, 100 µg.ml -1 streptomycin, and 2 mmol.l -1 Lglutamine in an incubator with 5% CO 2 .
Immunoprecipitation of Ilf3 and NF90 from P19 cell extract
After removal of the culture medium, P19 cells ( 10 7 ) were rinsed twice with prewarmed PBS. Cells were directly harvested in 0.5 ml hot lysis buffer (Tris-HCl 10 mmol.l -1 , pH 7.5, SDS 1% w/v) and boiled for 5 min. After five passages through a 25G needle, the total extract was sonicated and then centrifuged for 15 min at 20,000g and at 4°C to give the soluble fraction (SF). SF (100 µl) were diluted to 1 ml in RIPA buffer (Tris-HCl, 10 mmol.l -1 , pH 7.5; NaCl, 150 mmol.l -1 ; EDTA, 1 mmol.l -1
; EGTA, 1 mmol.l -1 ; Triton X-100, 1% v/v; Nonidet-P40, 0.5% v/v) and incubated at least 2 h at 4°C with 10 µl of antibody Ab78 in the presence of protease inhibitors. Protein A sepharose (30 µl) in RIPA (50%, v/v) was then added and incubated for 2 h at 4°C. After centrifugation for 15 s at 20,000g and at 4°C, the supernatant was carefully removed and the pellet was washed three times in RIPA buffer. The last pellet was solubilized in 185 µl of Laemmli buffer ×1 and submitted to 1-D PAGE and then to Northwestern blotting assay (see above). After autoradiography, membrane pieces corresponding to the radioactive signals were cut and radioactivity was quantified by liquid scintillation counting (Ultima Gold MV, Packard, Perkin Elmer).
Neuronal culture
Primary cultures of mouse brain neurons were prepared as described previously (20) with minor modifications. Briefly, 14.5-day-old embryos were removed from pregnant Albinos Swiss mice, and the cerebral hemispheres were dissected out into PBS-glucose (5 mg.ml -1 ). The meninges were carefully removed, and the cells were mechanically dissociated by gently passing the tissue several times through needles of decreasing sizes. The cells were then collected by centrifugation, rinsed once in PBS-glucose, and seeded on glass coverslips previously coated with polylysine (25 µg.ml -1 ) in Neurobasal Medium containing B27, 25.4 mmol.l -1 KCl, 100 U.ml -1 penicillin, 100 µg.ml -1 streptomycin, 2 mmol.l -1 glutamine, and 10% (v/v) heatinactivated fetal calf serum. After 24 h in vitro, the seeding medium was replaced with serumfree medium and the cultures were then half-renewed once a week.
Indirect immunofluorescence analysis
After 3 days in culture, cerebral cortical neurons were fixed for 60 min at room temperature in a microtubule-stabilizing buffer (0.1 mol.l -1 MES, pH 6.8, 2 mmol.l -1 MgCl 2 , 2 mmol.l -1 EGTA, 4% w/v polyethylene glycol 4000) containing 4% (w/v) paraformaldehyde. Subsequent steps were performed in PBS supplemented with 0.1% (v/v) Triton X-100 and 2% (v/v) normal goat serum. The cells were double-stained for 1 h at room temperature with either Ab78 (1:500 dilution) or Ab83 (1:200 dilution) together with either the anti-polyglutamylated tubulin GT335 monoclonal antibody (1:1000 dilution, see ref 21) or the anti-Tau Tau-1 monoclonal antibody (1:500 dilution, see ref 22) . Primary antibodies were then revealed using the Alexa Fluor 488 goat anti-rabbit (1:1000 dilution) or the Alexa Fluor 660 goat anti-mouse Igs (1:1000 dilution). Each incubation was followed by three successive PBS washes, and the coverslips were mounted onto glass slides in Mowiol. When needed, cells were incubated 10 min with PBS containing 4',6-diamidino-2-phenylindole (DAPI, 0.1 µg.ml -1 ) to visualize DNA and rinsed twice with PBS before mounting.
Subcellular fractionation of mouse brain
Preparation was carried out as previously described (23) with some minor modifications. Briefly, brains from 15-day-old mice were collected rapidly and homogenized in a Dounce with 5 ml homogeneization buffer per gram of tissue (50 mM HEPES, pH 7.6, 15 mM KCl, 2 mM EDTA, 2.4 M sucrose) supplemented with protease inhibitors. After 12 strokes, total extract was loaded onto a sucrose/glycerol cushion (10 mM HEPES, pH 7.6, 15 mM KCl, 2 mM EDTA, 2 M sucrose, glycerol 10% w/v) supplemented with protease inhibitors and centrifuged at 90,000g for 45 min. The supernatant and the cushion were carefully removed and then the pellet was resuspended in MEM buffer supplemented with proteases inhibitors. The three fractions were sonicated to break DNA, and the protein concentrations were determined using micro BCA kit assay (Pierce). Samples were used for Northwestern and Western blotting experiments.
RESULTS
It was previously shown that a segment of 91 nucleotides present in the 3' untranslated region of Tau mRNA is responsible for its axonal targeting (6) . This ATE RNA sequence was thus used as a probe in Northwestern blotting experiments to detect the interacting proteins (ATE-BPs) that could mediate the axonal targeting of the Tau mRNA and/or its stability. Total proteins extracted from embryonic to adult mouse brain were separated by 1-D PAGE, transferred onto nitrocellulose membrane, and overlaid with the [ 32 P]-labeled ATE probe. The level of ATE-BPs detected under these conditions was found to be maximal before birth and to decrease thereafter (data not shown). For practical reasons, further experiments were carried out with 15-day-old mouse brains. At this developmental stage, ATE-BPs are still at 50% of their maximal level and are qualitatively identical to those found before birth. Quantitatively, by overlaying increasing amounts of labeled ATE onto a constant amount of brain proteins, the apparent K d of ATE binding was estimated at ~5 nM. In addition, the radioactive ATE probe was efficiently displaced from ATE-BPs after addition of excess nonradioactive probe (data not shown).
Detection of ATE-BPs
Since it has been shown that Tau mRNA is transported attached to axonal MTs (9), we first tried to recover ATE-BPs by directly releasing them from MTs assembled from 15-day-old mouse brains (Fig. 1) . After MT assembly in the presence of GTP (P1) and their stabilization by Taxol (P2), MT-bound proteins were released by two salt washes at 0.1 M (S3) and 0.5 M (S4) NaCl (Fig. 1A) . Proteins from the different purification fractions were separated by 1-D PAGE and submitted to Northwestern blotting with the radioactive ATE probe (Fig. 1B) . In total mouse brain extracts (TE), three major ATE-BPs were detected (p110, p95, and p80) along with a few minor ones (with apparent MW at 150, 130, 75-70, 60, and 40 kDa, arrowheads in Fig. 1B) . Upon fractionation, most of these proteins remained in the insoluble crude pellet fraction (Po), an expected behavior for proteins belonging to RNA granules (11) tightly bound to stable, nondepolymerized MTs. Only faint traces of ATE-BPs were detected in the crude supernatant soluble fraction (So). However, when this fraction was submitted to MT assembly, the scarce ATE-BPs were efficiently recruited together onto MTs and further released by a salt wash with 0.1 M NaCl into the S3 fraction. Even with a low solubilization level of ATE-BPs, the results confirm that ATE-BPs interact with MTs.
Solubilization of p95 and p110
To characterize further the ATE-BPs mostly present in the insoluble Po fraction, we modified the homogeneization buffer to enhance their solubility. When mouse brains were homogenized into BICINE buffer at pH 9 in the presence of 0.5 M NaCl (see Materials and Methods), 70-80% of ATE-BPs were rendered soluble, as judged by their presence in the S2-BEM. Indeed, when proteins from this fraction were analyzed by 2-D PAGE and submitted to Northwestern blotting, p110, p95, and p80 were clearly resolved and detected by the radioactive ATE probe (Fig. 2A) . Superposition of Northwestern signals over a silver-stained duplicate 2-D gel (Fig. 2B) showed that the p95 signal colocalized with a well-defined stained spot, whereas the p110 and p80 signals did not match any detectable protein spot, indicative of their very low abundance.
Purification of p110
Partial purification of p110 was achieved through a five-step procedure (Fig. 3A) . After homogenization of 15-day-old mouse brains, proteins from the supernatant were precipitated, resuspended, and chromatographed successively on cation-exchange, anion-exchange, hydrophobic-interaction, and reverse-phase columns. At each step, proteins from each fraction were separated by 1-D SDS-PAGE and probed for their ability to bind the radioactive ATE probe by Northwestern assays. Fractions containing p110 were pooled and processed for the next chromatographic step. Starting from 130 mouse brains and after these different steps, p110 was estimated to have been enriched ~5000-fold, with an overall yield of 2.5%. Figure 3B shows the detection of p110 by Northwestern blotting in the fractions eluted from the last reverse-phase HPLC column. Proteins from fraction 14 were analyzed by 2-D PAGE, silver-stained (Fig. 3C) or probed by Northwestern blotting (Fig. 3D) . p110 was resolved as a doublet in the SDS-PAGE dimension and, in addition, displayed a substantial heterogeneity in the pI dimension of the 2-D gel, suggesting that p110 likely undergoes complex posttranscriptional/posttranslational modifications.
Identification of p110 by microsequencing
As the 2-D PAGE analysis of fraction 14 (Fig. 3C ) revealed the absence of any contaminating protein of the same size, p110 (3 µg) was isolated directly from 1-D PAGE gel and digested with endolysine-C. Proteolytic peptides were separated by an anion exchange coupled to a reversephase chromatography. Four of these peptides were microsequenced and displayed a complete identity to the previously cloned RNA binding protein interleukin enhancer binding factor 3 from mouse (mIlf3) (12) (Fig. 4A ). This protein comprises two dsRBM located at aa 417-478 and 540-601 (Fig. 4B) . Since the ATE RNA sequence was predicted to adopt a stem-loop structure-a large U-rich loop held at the tip of a long double-stranded RNA stem (Fig. 5 )-these dsRBM therefore represent potent interacting sites with the ATE probe (see Discussion). The identity of p110 as mIlf3 was also confirmed by Western blotting experiments using various antibodies (see below).
Use of anti-Ilf3 antibodies to further characterize p110 and p95
Rabbit polyclonal antibodies were raised against either a mixture of two synthetic N-terminal and central peptides (Ab78, aa 60-70 and 522-536) or a carboxy-terminal peptide (Ab83, aa 898-911) of mIlf3 (see Materials and Methods and Fig. 4B ). As control, we also used an anti-mIlf3 antibody from Braun's laboratory (12) raised against a large fragment of Ilf3 (aa 468-796) comprising the region of the two dsRBM and the downstream region (Fig. 4B) . Proteins from S2-BEM were separated by 2-D PAGE and submitted to Northwestern blotting with the radioactive ATE probe (Fig. 6A) or to Western immunoblotting using either Braun's anti-mIlf3 antibody (Fig. 6B) or Ab78 (Fig. 6C) or Ab83 (Fig. 6D) . p110, p95, and p80 were detected by Northwestern blotting (Fig. 6A ) as in Figure 2 . p110 and p95 were detected with Braun's Ab and Ab78 (Fig. 6B, 6C ) whereas only p110 was recognized by Ab83 (Fig. 6D) . These results confirm that p110 is Ilf3 and indicate that Ab83 is quite specific to Ilf3, in good agreement with database sequence analysis that showed that the carboxy-terminal peptide used to raise Ab83 is specific to Ilf3.
The experiments performed with Braun's Ab and Ab78 (Fig. 6B, 6C) showed that p95 was codetected with p110-Ilf3. These results indicate that Ilf3 and p95 share common amino-terminal and central epitopes. In addition, the use of Ab83 (Fig. 6D) showed that p95 differs from Ilf3 in its carboxy-terminal domain. Altogether, these results are in good agreement with the works reporting that the Ilf3 primary gene transcripts are alternatively spliced into, at least, two variants: Ilf3/NF110/NFAR2 and NF90/NFAR1 (13, 24) . The two corresponding protein variants share the first 701 aa residues but differ in their C-terminal sequences (aa 702-716 for NF90/NFAR2 and aa 702-911 for Ilf3/NF110/NFAR1). These data strongly suggest that p95 is NF90.
Concerning p95, as the Northwestern signal corresponded to a well-defined protein spot in 2-D gels (see Fig. 2 ), several such spots had been first cut from 2-D gels and submitted to endolysine-C digestion. After fractionation of the resulting peptides by HPLC, three of them had been sequenced, showing 100% identity to mouse aconitase (25) , strongly suggesting that p95 could have been aconitase (data not shown). However, given the results obtained after the Western blotting experiments described above, we concluded that aconitase was not p95. It appears that aconitase is an abundant protein that displays the same 2-D electrophoretic coordinates than the far less abundant p95-NF90 species, which represents the very target of the ATE probe.
To confirm the identification of p95 as NF90, we immunoprecipitated Ilf3 and p95/NF90 from P19-soluble cell extract using antibody Ab78. The resulting pellet and supernatant were processed for Northwestern blotting using the radioactive ATE RNA sequence as probe. After autoradiography, the radioactivity associated with Ilf3 and p95/NF90 signals was quantified by liquid scintillation counting. As shown in Figure 6E , Ilf3 and NF90, partially immunodepleted from the soluble P19 extract (by ~20% and ~35%, respectively), were clearly probed by the ATE RNA sequence after Northwestern blotting. This result indicates that NF90 and p95 correspond to the very same protein species detected by both Ab78 and the ATE probe.
Ilf3/NF90 immunolocalization in primary cultured neurons
Ab83 was first used to specifically immunolocalize Ilf3. Cultured mouse cortical neurons were processed for indirect, double-immunofluorescence with either Ab83 (Fig. 7A) and GT335 (Fig.  7B) , a monoclonal antibody that recognizes polyglutamylated tubulin, highly abundant in all neuronal compartments (21), or with Ab83 (Fig. 7C ) and the monoclonal antibody Tau-1 (Fig.  7D) , specific for Tau proteins (22) . After a 3-day culture, the neuronal cell bodies and the proximal part of axons were intensively stained with Ab83 (large arrow in Fig. 7A, 7C , and 7E), whereas nuclei revealed by DAPI staining were hardly stained with Ab83 (thin arrow in Fig. 7E,  7F ). The continuing parts of the axonal processes stained by Tau-1 (thin arrow in Fig. 7D ), as well as the dendritic branches stained by GT335 (thin arrow in Fig. 7B) were not stained at all by Ab83 (corresponding thin arrows in Fig. 7A, 7C ). These results are in good agreement with the previously reported localization of Tau mRNA in neuronal cell bodies and axon hillock (5, 26) .
Ab78, which recognizes both Ilf3 and NF90, was also used in immunofluorescence studies on neuronal cells at 2 days and 13 days of culture (data not shown). At an early stage of neuronal differentiation, Ab78 stained almost only neuronal nuclei. A substantial staining then appeared and increased in intensity into the cytoplasm as differentiation proceeded.
The results obtained with Ab83 and Ab78 could appear somewhat puzzling. Indeed, with Ab78 alone, it could be concluded that Ilf3 and NF90 are essentially restricted to the nuclear compartment. The use of Ab83, however, clearly indicates that it is not the case and that, at least for Ilf3, this protein is also present in the cytoplasm. In turn, the fact that Ab83 cannot detect Ilf3 within the nucleus may suggest the existence of an alternative epitope availability between the two cellular compartments, the Ab83 epitope being masked in the nucleus and, conversely, the Ab78 epitope being masked in the cytoplasm. Moreover, Ilf3 and NF90 were detected in both nuclear and cytoplasmic fractions purified after brain fractionation by Western and Northwestern blotting experiments (Fig. 7E) . These observations suggest the possibility of such an alternative epitope availability that probably reflects the selective interactions of these protein domains with associated RNA or nuclear/cytoplasmic proteins.
DISCUSSION
In developing organisms as well as in differentiated cells, a large number of mRNAs are asymmetrically localized into the cytoplasm. This selective localization is due to the interaction of specific RNA sequences and/or structural motifs (cis-acting elements) with trans-acting proteins. In neurons, some mRNAs are delivered to specific subcellular compartments (27) , notably those coding for Tau and MAP2, which are preferentially localized in axons and dendrites, respectively (5). The particular distributions of Tau and MAP2 proteins, favored by the prelocalization of their mRNA, may explain neuronal asymmetry. It has previously been shown that the selective translocation of Tau mRNA in axons relies on the integrity of MTs (9) and is due to a 91-nucleotide segment present in the 3' untranslated region of Tau mRNA (6), serving as ATE RNA.
The predicted stem-loop structure of ATE (Fig. 5) could represent a multisite signal for the recruitment of specific regulatory proteins. For example, it has been shown that HuD-an ELAV-like protein-interacts in vivo with Tau mRNA and stabilizes it (8) . In the case of the mammalian signal recognition particle (SRP) involved in the cotranslational targeting of proteins to the endoplasmic reticulum membranes, a 300-nucleotide RNA (7SL RNA) structured into complex double-stranded stems and loops serves as a scaffold to bind six different proteins, each interacting with a limited number of RNA base pairs (for review, see ref 28) . Thus, the structured 91-nucleotide Tau mRNA ATE appears to be large enough to directly interact with several binding proteins that can, each in turn, bind other ones.
Using this ATE RNA sequence as a probe in a Northwestern approach, we have detected several ATE-BPs that specifically interact with this targeting sequence with high affinity. Moreover, two of them characterized so far, Ilf3 and NF90, contain peptidic motifs specialized to bind singlestranded RNA (RGG motif) as well as double-stranded RNA (dsRBM).
Since Tau mRNA transport depends on the integrity of MTs (9), we first attempted to recover the ATE-BPs by purifying them directly from brain MTs. Unfortunately, most of the ATE-BPs detected in total brain extracts fractionated directly into the insoluble pellet ( Fig. 1) , which led us to define particular extraction and solubilization procedures (Fig. 3) . Nonetheless, assembly of MT from the supernatant fraction enabled the scarce soluble ATE-BPs present in this fraction to be efficiently recruited, suggesting a rather high affinity of these proteins for MTs. Most likely, the different ATE-BPs segregate together as a multiprotein complex that interacts with Tau mRNA via its ATE in the form of an RNA granule. This may also explain the high abundance of ATE-BPs in the insoluble crude pellet fraction, reflecting their tight association with cold-stable, non-depolymerized MT largely present in brain pellets. Within this protein complex, a single MT binding protein, for instance, a motor protein, may be sufficient to anchor the complex to MTs and translocate Tau mRNA in the direction of axon. The neuronal KIF3A could represent this motor activity since its inhibition was recently reported to abrogate Tau mRNA transport (10).
Using a five-step procedure (Fig. 3) , a partial purification of p110 was achieved and, after amino acid sequencing, p110 was identified as the mIlf3, a protein characterized for its ability to interact with the 3′ untranslated region of the protamine-1 mRNA (12). Ilf3 belongs to a protein family whose members share one to five double-stranded RNA binding motifs (dsRBM) and are involved in mRNA localization (29, 30) and translational activation or processing of rRNA precursors (for review, see ref 31). 2-D PAGE analysis revealed a complex heterogeneity of the protein, more than eight spots being resolved in the pI dimension and at two levels of migration in the SDS-PAGE dimension (Fig. 6 ).
Slight differences in the size of Ilf3 could be due to a proteolytic maturation, a phosphorylationinduced migration shift, and/or an alternative splicing, as has been reported for human Ilf3 (24) . Beyond these small differences observed in the SDS-PAGE dimension, a larger alternative splicing event was reported to be responsible for the synthesis of a NF90 variant (13, 24) . NF90 shares the first 701 aa residues with p110-Ilf3 but differs by its shorter carboxy-terminal sequence (aa 702-716, compared with the larger aa 702-911 specific sequence of Ilf3). Moreover, the Ab78 antibody, prepared against amino-terminal and central common epitopes, detected p110-Ilf3 and p95 as well (Fig. 6C) . Likewise, both proteins were probed by the antimIlf3 Braun's antibody (12) raised against a large central domain of Ilf3. On the contrary, the Ab83 antibody, specific for the extreme carboxy-terminal sequence of Ilf3, did not recognize p95 at all (Fig. 6D) , which led us to assume that p95 is indeed NF90. Moreover, p95 was also probed by a commercial anti-NF90 monoclonal antibody (data not shown). The identification of p95 as NF90 was also reinforced by the immunodepletion experiment of a soluble P19 cell extract with Ab78: the same proteins immunoprecipitated with this antibody did bind also to the ATE RNA probe. The large domain identity shared by p95/NF90 and p110/Ilf3 could also explain the strong similarity of their heterogeneous protein patterns obtained after 2-D PAGE (Fig. 6 ), since both proteins may undergo, for instance, similar posttranslational modifications within their large common sequence.
The second aspect of Ilf3 and NF90 polymorphism observed in the pI dimension of 2-D gels could be the consequence of several posttranslational modifications such as phosphorylation and/or arginine methylation. Phosphorylation of human Ilf3 has already been reported (32) . By computer analysis of the mIlf3 sequence, many putative phosphorylation sites by several kinases can be pointed out, some being located within or close to signal sequences such as NLS, NES, or dsRBM, that is, in the right places to regulate interaction with RNA and/or the other proteins of the complex, or to regulate the nuclear import/export of the protein.
Another posttranslational modification, arginine methylation, can also occur on Ilf3. Methylation slightly modifies the pI and could explain part of the Ilf3/NF90 heterogeneity observed in 2-D gels. Indeed, it has been reported that Ilf3 is a substrate of protein-arginine methyltransferase 1 (33) . Arginine methylation is a widely used posttranslational modification, particularly in signaling and in nucleocytoplasmic trafficking pathways. hnRNPs involved in pre-mRNA maturation and nucleocytoplasmic RNA transport (34, for review see ref 35) are extensively methylated on RGG consensus motifs, arginine methylation being essential to their functions. Other RNA binding proteins, such as fibrillarin, are also methylated (36, 37) . It is thought that addition of methyl groups replaces N-linked hydrogen atoms that could be engaged in hydrogen bonding, suggesting that arginine methylation may regulate protein-protein as well as protein-RNA interactions. The RGG sequence is also the signature of an RNA binding motif and is present in the common Ilf3-NF90 sequence downstream of the two dsRBM (Fig. 4) . Methylation of this RGG site within the complex RNA binding domain could then likely modulate the interaction between Ilf3-NF90 and Tau mRNA. Antibody Ab83 was shown by Western blotting to be strictly specific for Ilf3 (Fig. 6D) . By indirect immunofluorescence analysis (Fig. 7) , Ab83 labeled cell bodies and typical cone-shaped areas, which likely correspond to the emergence regions of axons. Since this staining overlaps the previously described cellular localization of Tau mRNA in neurons (5), this result is coherent with the idea that Ilf3 could accompany Tau mRNA up to the proximal segment of the axon.
The other antibody, Ab78, was shown to detect both Ilf3 and NF90 to the same extent in Western blotting experiments (Fig. 6C ). In addition, Ab78 also has the property to immunoprecipitate both proteins (Fig. 6E) , indicating that it can also recognize them under their native state. In immunofluorescence studies, Ab78 gave a complementary staining pattern relative to Ab83 and decorated essentially neuronal nuclei, although the staining spread into the cytoplasm with the time of culture (data not shown). Since Ab83 detects Ilf3 mostly in the cytoplasm and Ab78 stains mainly nuclei, this could mean that the Ab83 epitope or the Ab78 epitopes are selectively masked in the nucleus and in the cytoplasm, respectively. Moreover, the physical presence of both Ilf3 and NF90 has been confirmed in purified brain nuclear and cytoplasmic fractions by Western and Northwestern blotting (Fig. 7G) . In addition, Ilf3 has been reported to shuttle between nuclear and cytoplasmic compartments (38, 39) . This alternative nuclear/cytoplasmic epitope availability on Ilf3 and NF90 could be related to the shuttle of both proteins between the two compartments to load Tau mRNA (or pre-mRNA) in the nucleus and deliver the messenger onto cytoplasmic microtubules en route for the axon. Indeed, the various steps of the shuttle pathway should imply successive interactions with RNA and distinct proteins, for instance, those dealing with the NLS/NES signals as well as the posttranslational modification enzymes (arginine methylase, protein kinases, phosphatases) or other escort proteins. This hypothesis remains compatible with the idea that Ilf3 and NF90 could share complementary and successive roles, the presence or the absence of the ~200-aa-long carboxy-terminal domain making the functional difference between the two proteins. This is especially relevant because the Ilf3 carboxy-terminal domain contains several Gly/Ser/Pro-rich sequences predicted to fold into exposed loops representing potential interaction sites (33) . Whatever this functional difference may be, it has yet to be elucidated. Like Ilf3 and NF90, another protein species detected by Northwestern experiments, p80, displays a high affinity for the ATE sequence (see Fig. 1 and 2 ) but wasn't probed with Ab83, Ab78 or with the Braun's anti-mIlf3 antibody (see Fig. 6 ). These results suggest that p80 is an unrelated, different protein whose identification has yet to be carried out.
Experiments are in progress to characterize the other unidentified ATE-BPs detected by Northwestern blotting as well as proteins belonging to the Tau RNP complexes, which indirectly bind to Tau mRNA using primary ATE-BP as intermediates and which hence cannot be directly detected by the ATE probe by a Northwestern approach. Given that drastic conditions are necessary to solubilize Ilf3 and NF90 from insoluble complexes in crude brain extracts, characterization of their protein partners cannot be envisaged easily by simple immunoprecipitation methods. To this end, alternative techniques have been initiated. 32 P]-labeled ATE probe. Three major proteins (arrows) and other minor ones (arrowheads) were detected in the total extract (TE). Fraction Z corresponds to the sucrose cushion used to efficiently lower the contamination of the crude MT pellet (P1) by non-MT proteins (S1). Molecular weights are indicated at right. . in B) . This fraction was centrifuged to eliminate insoluble material into the pellet (P in B), and the supernatant was loaded onto a C4 reverse-phase chromatography column. Proteins from fractions eluted from the C4 column were separated by SDS-PAGE and submitted to Northwestern blotting with the [ 32 P]-labeled ATE probe (B). Fraction 14, which gave the strongest signal, was subjected to 2D-PAGE (C and D, acidic side at the right). Proteins were either detected by silver staining (C) or probed by Northwestern blotting with the 4 . Amino acid sequencing of purified p110. Fraction 14 from reverse-phase HPLC was submitted to 1D PAGE, and the p110 protein band was excised and treated with endolysine-C. After anion exchange coupled to reverse-phase HPLC, four peptides were sequenced according to the Edman protocol and their sequences were compared with the mouse Ilf3 sequence (12) . The four sequenced peptides are scattered among the 911 aminoacids long mIlf3 sequence (A). B) Locations of the putative nuclear localization signal (NLS) are shown, and the two double-strand RNA binding motifs (dsRBM) and the RGG motif (RGG) are indicated. The amino acid sequences of the peptides used to raise specific polyclonal antibodies are also indicated, a mix of two peptides corresponding to the amino-terminal aa 60-70 and central aa 522-536 for antibody 78 (Ab78), and the carboxy-terminal aa 898-911 for antibody 83 (Ab83). 
